Markets:

Overview

News

Currencies

International

Treasuries

Moleculin Biotech, Inc. - Common Stock (NQ:MBRX)

0.3573 -0.0088 (-2.40%)

Streaming Delayed Price Updated: 10:41 AM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Moleculin Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Earnings Scheduled For March 21, 2025 ↗

March 21, 2025

Via Benzinga

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week ↗

March 02, 2025

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

Via Stocktwits

Which stocks are experiencing notable movement on Tuesday? ↗

February 25, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

What's going on in today's pre-market session ↗

February 25, 2025

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

Insights Ahead: Moleculin Biotech's Quarterly Earnings ↗

November 07, 2024

Via Benzinga

Unusual volume stocks in Tuesday's session ↗

February 18, 2025

Let's have a look at the stocks with an unusual volume in today's session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 18, 2025

Via Benzinga

Top 5 Biotech Stocks That Got Most Retail Buzz Last Week ↗

February 17, 2025

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

Via Stocktwits

Friday's session: top gainers and losers ↗

February 14, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

Check out the stocks that are attracting the most attention and driving market activity. ↗

February 14, 2025

Let's dive into the action on the US markets on Friday. Here are the most active stocks that are driving the market today.

Via Chartmill

Unusual volume stocks in Friday's session ↗

February 14, 2025

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

Via Chartmill

What's going on in today's session ↗

February 14, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

Top movers in Friday's pre-market session ↗

February 14, 2025

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 14, 2025

Via Benzinga

US Stocks Set For A Volatile Start: Analyst Dismisses Chances Of 20%+ S&P 500 Gain For Third Year In A Row, But Says 'Investors Should Be Optimistic' ↗

February 14, 2025

U.S. stock futures traded close to the flatline on Friday after Tuesday's rally. Futures of all four benchmark indices were slightly lower.

Via Benzinga

Topics Stocks

Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

February 14, 2025

Via Benzinga

Keep an eye on the top gainers and losers in Thursday's session. ↗

February 13, 2025

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Via Chartmill

The trading volume of these stocks is deviating from the norm in today's session. ↗

February 13, 2025

The trading volume of these stocks is deviating from the norm in today's session.

Via Chartmill

Which stocks are moving on Thursday? ↗

February 13, 2025

Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday? ↗

February 13, 2025

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in late 2025, with another in 2026.

Via Benzinga

Thursday's session: gap up and gap down stocks ↗

February 13, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Unusual volume stocks in Wednesday's session ↗

February 12, 2025

On Wednesday, there are stocks with unusual volume. Let's take a look.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 06, 2025

Via Benzinga

Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗

February 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 11, 2024

Via Benzinga

What's Going On With Moleculin Biotech Shares Wednesday? ↗

December 11, 2024

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model.

Via Benzinga

MBRX Stock Earnings: Moleculin Biotech Beats EPS for Q2 2024 ↗

August 14, 2024

MBRX stock results show that Moleculin Biotech beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 14, 2024

Via Benzinga

MBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024 ↗

May 10, 2024

MBRX stock results show that Moleculin Biotech beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 26, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.